Nexcella Inc. Presents Breakthrough Poster at the European CAR T-Cell Meeting

Come join us in Rotterdam, Netherlands February 9-11, 2023 for the presentation of updated clinical data on NXC-201, a next-generation CAR-T treatment for multiple myeloma and AL amyloidosis. Don’t miss this unique opportunity to learn more about this revolutionary therapy and explore its potential applications.

Nexcella Inc., a leading biopharmaceutical company dedicated to the discovery and development of innovative cell therapies for oncology and other applications, is proud to announce that their latest NXC-201 clinical data will be featured at the upcoming 5th Annual European CAR T-cell Meeting in Rotterdam, Netherlands, happening from February 9-11, 2023. This is an incredible opportunity for the company to showcase their groundbreaking work and share their vision for the future of cell therapy.

The Hadassah Medical Organization is thrilled to be showcasing further clinical data at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting. As the team continues to accrue clinical data, they are gaining an ever-deepening understanding of the potential of this therapy to treat both multiple myeloma and AL amyloidosis. Polina Stepensky, MD, Director of the Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children and principal study investigator, is leading the way.

Posters to be presented:

At Hadassah Medical Center, an innovative point-of-care CAR-T manufacturing and delivery system is being used to treat multiple myeloma and AL amyloidosis. Nexcella’s NXC-201 treatment has produced a remarkable 85% overall response rate (ORR) and 71% complete response/stringent complete response (CR/sCR) in the first 20 patients in an ongoing phase 1b/2a relapsed/refractory multiple myeloma trial. Moreover, the same treatment has shown a 100% organ response rate and zero neurotoxicity in AL Amyloidosis patients. What’s more, the low-grade (grade 1/2) cytokine release syndrome (CRS) observed in patients has a median duration of just 2 days and median onset of 1 day post-dosing. These promising results suggest that NXC-201 could become the first and only out-patient CAR-T for multiple myeloma, AL amyloidosis, and other BCMA-positive malignancies.


NEXICART-1 (NCT04720313) is an exciting Phase 1b/2 clinical trial, testing the groundbreaking drug NXC-201 (formerly HBI0101) on adults with relapsed or refractory multiple myeloma. As of June 27, 2022, all participants are triple-class refractory, meaning they have not responded to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies. The Phase 1b portion of the study is working to establish the safety and maximum tolerated dose, while the Phase 2 portion will evaluate efficacy and safety, with the aim of improving overall survival and progression-free survival. Results will be assessed by the International Myeloma Working Group (IMWG) Uniform Response Criteria.

About NXC-201

NXC-201 is an exciting new investigational CAR-T cell therapy designed specifically to target and treat patients with relapsed or refractory multiple myeloma and amyloidosis. Our proprietary BCMA-targeting CAR technology has been carefully engineered to reduce toxicity and offer the potential of outpatient therapy. The results of the NEXICART-1 study are particularly encouraging, showing the potential of NXC-201 to revolutionize the treatment of these serious diseases.

About Multiple Myeloma

Myeloma, an incurable blood cancer, affects 34,470 people in the US each year. It begins in the bone marrow and causes an excessive growth of plasma cells. Although initial remission is possible, its prognosis is poor for those who fail to respond to treatments such as protease inhibitors and immunomodulators – or those who relapse after treatment.

About Nexcella, Inc.

Nexcella, Inc. is more than just a subsidiary of Immix Biopharma, Inc (NASDAQ:IMMX). We are a clinical-stage biopharmaceutical company on the cutting edge of biotechnology, using our innovative N-GENIUS platform to develop novel cell therapies with the potential to revolutionize oncology and other medical treatments. Our mission is to bring groundbreaking therapeutic solutions to patients in need and make a real difference in people’s lives.

Forward Looking Statements

Immix Biopharma, Inc. is constantly looking ahead to the future, with a focus on our business strategy, future operating results and liquidity and capital resources outlook. Our forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. However, due to the inherent uncertainties, risks and changes in circumstances associated with these statements, our actual results may differ significantly from our expectations. Important factors that could cause actual results to differ materially from those anticipated include our ability to raise capital, protect our intellectual property rights, compete with other providers and products, develop and commercialize products and services, and comply with government regulation. To ensure a successful future, Immix Biopharma, Inc. is dedicated to monitoring and managing these risks.

It is impossible to predict all the factors and events that could lead to unexpected results in the future. There is no way to ensure our future success, activity, performance, or accomplishments. However, we are always learning and adapting to any changes that may arise, with the goal of striving for the best possible outcomes.

Leave a Comment